Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain

Bipolar Disorders

Volumn 12, Issue 4, 2010, Pages 414-424

  Brocardo, Patrícia S ^a   Budni, Josiane ^a   Pavesi, Eloísa ^a   Franco, Jeferson L ^a   Uliano Silva, Marcela ^a   Trevisan, Rafael ^a   Terenzi, Mariana G ^a   Dafre, Alcir L ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Bipolar disorder; Folic acid; Mania; Ouabain; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; FOLIC ACID; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LITHIUM CHLORIDE; MOOD STABILIZER; OUABAIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MALE; MANIA; MENTAL DISEASE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANIMALS; ANTIMANIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; FOLIC ACID; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; LITHIUM CHLORIDE; MALE; MOTOR ACTIVITY; OUABAIN; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 77954853791     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00827.x     Document Type: Article

References (72)

1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
2. Savas HA, Gergerlioglu HS, Armutcu F. Toward an understanding of bipolar disorder and its origin. J Clin Psychiatry 2003, 64:4-8.
3. Calabrese JR, Hirschfeld RM, Reed M. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003, 64:425-432.
4. Andreazza AC, Frey BN, Erdtmann B. DNA damage in bipolar disorder. Psychiatry Res 2007, 153:27-32.
5. Frey BN, Andreazza AC, Kunz M. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:283-285.
6. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan E, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
7. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95.
8. Ranjekar PK, Hinge A, Hegde MV. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
9. Machado-Vieira R, Andreazza AC, Viale CI. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
10. Frey BN, Valvassori SS, Réus GZ. Changes in antioxidant defense enzymes after D-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006, 31:699-703.
11. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 2006, 8:275-280.
12. Frey BN, Valvassori SS, Réus GZ. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
13. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005, 58:879-884.
14. El-Mallakh RS, Wyatt RJ. The Na,K-ATPase hypothesis for bipolar illness. Biol Psychiatry 1995, 37:235-244.
15. Herman L, Hougland T, El-Mallakh RS. Mimicking human bipolar ion dysregulation models mania in rats. Neurosci Biobehav Rev 2007, 31:874-881.
16. Rose AM, Mellett BJ, Valdes R. Alpha 2 isoform of the Na,K-adenosine triphosphatase is reduced in temporal cortex of bipolar individuals. Biol Psychiatry 1998, 44:892-897.
17. Decker S, Grider G, Cobb M. Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:455-462.
18. El-Mallakh RS, Harrison LT, Li R, Changaris DG, Levy RS. An animal model for mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:955-962.
19. El-Mallakh RS, El-Masri MA, Huff MO, Li X-P, Decker S, Levy RS. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 2003, 5:362-365.
20. Li R, El-Mallakh RS, Harrison L, Changaris DG, Levy RS. Lithium prevents ouabain-induced behavioral changes. Toward an animal model for manic depression. Mol Chem Neuropathol 1997, 31:65-72.
21. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993, 27:138-145.
22. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994, 331:591-598.
23. Djukic A. Folate-responsive neurologic diseases. Pediatr Neurol 2007, 37:387-397.
24. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996, 54:382-390.
25. Dhitavat S, Ortiz D, Rogers E, Rivera E, Shea TB. Folate, vitamin E, and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid-beta. Brain Res 2005, 1061:114-117.
26. Joshi R, Adhikari S, Patro BS, Chattopadhyay S, Mukherjee T. Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity. Free Radic Biol Med 2001, 30:1390-1399.
27. Rezk BM, Haenen GR, van der Vijgh WJ, Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett 2003, 555:601-605.
28. Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006, 5:949-960.
29. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1103-1112.
30. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005, 19:59-65.
31. Brocardo PS, Budni J, Kaster MP, Santos ARS, Rodrigues ALS. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology 2008, 54:464-473.
32. Brocardo PS, Budni J, Lobato KR, Kaster MP, Rodrigues ALS. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008, 598:37-42.
33. Hasanah CI, Khan UA, Musalmah M, Razali SM. Reduced red-cell folate in mania. J Affect Disord 1997, 46:95-99.
34. Ozbek Z, Kucukali CI, Ozkok E. Effect of the methylenetetrahydrofolate reductase gene polymorphisms on homocysteine, folate and vitamin B12 in patients with bipolar disorder and relatives. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1331-1337.
35. Carney MW, Chary TK, Laundy M. Red cell folate concentrations in psychiatric patients. J Affect Disord 1990, 19:207-213.
36. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986, 10:9-13.
37. Coppen A, Abou-Saleh MT. Plasma folate and affective morbidity during long-term lithium therapy. Br J Psychiatry 1982, 141:87-89.
38. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates 1998, San Diego, Academic Press
39. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
40. Wendel A. Glutathione peroxidase. Methods Enzymol 1981, 77:325-332.
41. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 1985, 113:484-489.
42. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
43. Bertholf RL, Savory MG, Winborne KH, Hundley JC, Plummer GM, Savory J. Lithium determined in serum with an ion-selective electrode. Clin Chem 1988, 34:1500-1502.
44. Young AH, Newham JI. Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol 2006, 20:17-22.
45. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behav Pharmacol 1990, 1:469-490.
46. Machado-Vieira R, Schmidt AP, Avila TT. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sci 2004, 76:805-811.
47. Severus WE, Kleindienst N, Seemüller F, Frangou S, Möller HJ, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder - a review? Bipolar Disord 2008, 10:231-237.
48. Walz JC, Frey BN, Andreazza AC. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 2008, 42:416-421.
49. Schuster O, Weimann HJ, Müller J, Menke A, Menke G. Pharmacokinetics and relative bioavailability of iron and folic acid in healthy volunteers. Arzneimittelforschung 1993, 43:761-766.
50. Gregory JF, Bhandari SD, Bailey LB, Toth JP, Baumgartner TG, Cerda JJ. Relative bioavailability of deuterium-labeled monoglutamyl tetrahydrofolates and folic acid in human subjects. Am J Clin Nutr 1992, 55:1147-1153.
51. Matté C, Durigon E, Stefanello FM, Cipriani F, Wajner M, Wyse AT. Folic acid pretreatment prevents the reduction of Na+,K+-ATPase and butyrylcholinesterase activities in rats subjected to acute hyperhomocysteinemia. Int J Dev Neurosci 2006, 24:3-8.
52. Savas HA, Gergerlioglu HS, Armutcu F. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006, 7:51-55.
53. Xie Z, Kometiani P, Liu J, Li J, Shapiro JI, Askari A. Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 1999, 274:19323-19328.
54. Boldyrev A, Bulygina E, Gerassimova O, Lyapina L, Schoner W. Functional relationship between Na/K-ATPase and NMDA-receptors in rat cerebellum granule cells. Biochemistry 2004, 69:429-434.
55. Kennedy DJ, Vetteth S, Xie M. Ouabain decreases sarco(endo)plasmic reticulum calcium ATPase activity in rat hearts by a process involving protein oxidation. Am J Physiol Heart Circ Physiol 2006, 291:H3003-H3011.
56. Boldyrev A, Bulygina E, Makhro A. Glutamate receptors modulate oxidative stress in neuronal cells. A mini-review. Neurotox Res 2004, 6:581-587.
57. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998, 95:2642-2647.
58. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004, 43:200-227.
59. Andreazza AC, Kauer-Sant'anna M, Frey BN. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144.
60. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003, 116:485-489.
61. Gliszczyńska-Swigło A, Muzolf M. A pH-Dependent radical scavenging activity of folates. J Agric Food Chem 2007, 55:8237-8242.
62. Chiarello PG, Vannucchi MT, Moysés Neto M, Vannucchi H. Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid. Int J Vitam Nutr Res 2003, 73:431-438.
63. McCarty MF. High-dose folate may improve platelet function in acute coronary syndrome and other pathologies associated with increased platelet oxidative stress. Med Hypotheses 2007, 69:12-19.
64. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009, 30:6-15.
65. El-Mallakh RS, Decker S, Morris M. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1261-1264.
66. Malek FA, Möritz KU, Fanghänel J, Bienengräber V. Sex-related differences in procarbazine-induced cleft palate and microgenia and the anti-teratogenic effect of prenatal folic acid supplementation in rats. Ann Anat 2003, 185:465-470.
67. Baydar T, Nagymajtényi L, Isimer A, Sahin G. Effect of folic acid supplementation on aluminum accumulation in rats. Nutrition 2005, 21:406-410.
68. Marsillach J, Ferré N, Camps J, Riu F, Rull A, Joven J. Moderately high folic acid supplementation exacerbates experimentally induced liver fibrosis in rats. Exp Biol Med 2008, 233:38-47.
69. Miao Y, Zhang Y, Lim PS. Folic Acid Prevents and Partially Reverses Glucocorticoid-Induced Hypertension in the Rat. Am J Hypertens 2007, 20:304-310.
70. Burdge GC, Lillycrop KA, Phillips ES, Slater-Jefferies JL, Jackson AA, Hanson MA. Folic acid supplementation during the juvenile-pubertal period in rats modifies the phenotype and epigenotype induced by prenatal nutrition. J Nutr 2009, 139:1054-1060.
71. Stokstad EL, Reisenauer A, Kusano G, Keating JN. Effect of high levels of dietary folic acid on folate metabolism in vitamin B12 deficiency. Arch Biochem Biophys 1988, 265:407-414.
72. Technical Report Series, 934. Evaluation of Certain Food Additives: Sixty-Fifth Report of the Joint FAO/WHO. Expert Committee on Food Additives 2006, Geneva, WHO